Ira Glick
Psychiatry · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Ira Glick’s office at (650) 498-5710 to ask if they take your plan before you enroll.
California Medical Board record
Licence G9084 · Current
Licensed to practise in California · since 1963 · expires 2027-10-31 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$7,417
Pharmacies billed $7,417 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 95) in 2024. At or below the middle of the specialty; the typical psychiatry & neurology clinician is at 0%.
95 generic and 0 brand-name prescriptions · $7,417 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clozapine | 27 | $4,720 | $175 |
| Quetiapine | 12 | $1,649 | $137 |
| Imipramine | 12 | $224 | $19 |
| Risperidone | 17 | $113 | $7 |
Year by year
| 2024 | 95 | None | 0% (0) | 0% | $7,417 |
| 2023 | 102 | None | 0% (0) | 0% | $7,031 |
| 2022 | 99 | None | 0% (0) | 14% | $111,345 |
| 2021 | 98 | None | 0% (0) | 0% | $5,974 |
| 2020 | 107 | None | 0% (0) | 0% | $6,033 |
| 2019 | 121 | 11 | 0% (0) | 9% | $12,305 |
| 2018 | 112 | 13 | 0% (0) | 13% | $9,975 |
| 2017 | 128 | 18 | 0% (0) | 9% | $12,424 |
| 2016 | 140 | 21 | None | 16% | $15,172 |
| 2015 | 103 | 14 | 0% (0) | 12% | $10,778 |
| 2014 | 113 | 14 | 0% (0) | 18% | $23,652 |
| 2013 | 112 | 16 | 0% (0) | 16% | $29,025 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Clozapine | 32 | $3,233 | $101 |
| Quetiapine | 13 | $1,548 | $119 |
| Olanzapine | 11 | $1,365 | $124 |
| Imipramine | 11 | $187 | $17 |
| Lithium Carbonate | 12 | $40 | $3 |
2022: 3 drugs
| Ingrezza | 14 | $103,931 | $7,424 |
| Clozapine | 28 | $4,651 | $166 |
| Imipramine | 13 | $228 | $18 |
2021: 3 drugs
| Clozapine | 40 | $4,322 | $108 |
| Imipramine | 11 | $158 | $14 |
| Lithium Carbonate | 13 | $54 | $4 |
2020: 3 drugs
| Clozapine | 37 | $4,284 | $116 |
| Imipramine | 13 | $183 | $14 |
| Lithium Carbonate | 17 | $149 | $9 |
2019: 5 drugs
| Clozapine | 40 | $6,892 | $172 |
| Divalproex Sodium Er | 12 | $255 | $21 |
| Risperidone | 12 | $126 | $10 |
| Imipramine | 12 | $121 | $10 |
| Lithium Carbonate | 15 | $96 | $6 |
2018: 2 drugs
| Clozapine | 39 | $6,637 | $170 |
| Lithium Carbonate | 15 | $119 | $8 |
2017: 5 drugs
| Clozapine | 37 | $7,151 | $193 |
| Aripiprazole | 12 | $3,830 | $319 |
| Olanzapine | 14 | $374 | $27 |
| Lithium Carbonate | 19 | $160 | $8 |
| Quetiapine | 11 | $140 | $13 |
2016: 5 drugs
| Clozapine | 30 | $6,540 | $218 |
| Olanzapine | 12 | $383 | $32 |
| Risperidone | 14 | $349 | $25 |
| Lithium Carbonate | 18 | $153 | $9 |
| Lorazepam | 19 | $148 | $8 |
2015: 4 drugs
| Clozapine | 32 | $7,413 | $232 |
| Risperidone | 21 | $179 | $9 |
| Lithium Carbonate | 14 | $102 | $7 |
| Lorazepam | 14 | $46 | $3 |
2014: 3 drugs
| Clozapine | 27 | $5,746 | $213 |
| Risperidone | 24 | $376 | $16 |
| Lorazepam | 14 | $43 | $3 |
2013: 2 drugs
| Clozapine | 41 | $8,907 | $217 |
| Risperidone | 17 | $750 | $44 |
Money from drug and device companies
$89 in 2024
| 2024 | 1 | 1 | None | $89 |
| 2023 | 1 | 1 | None | $23 |
| 2022 | 2 | 4 | None | $175 |
| 2021 | 2 | 2 | None | $176 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lundbeck | Abilify Asimtufii | $89 | 1 payment
|
See the published payment
| Lundbeck | Meals · 2024-08-05 | Abilify Asimtufii | $89 |
See earlier years (2023, 2022, 2021)
2023: $23
| Alkermes | Aristada | $23 | 1 payment
|
2022: $175
| Neurocrine Biosciences | Ingrezza | $140 | 3 payments
|
| Merck Sharp & Dohme | Capvaxive | $35 | 1 payment
|
2021: $176
| Iti | Caplyta | $104 | 1 payment
|
| Avanir Pharmaceuticals | None | $73 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Axsome Therapeutics, Inc. · A Randomized, Double-Blind, Active-Controlled Study of Axs-05 for the Prevention of Relapse of Depressive Symptoms · 2025 | Their institution | $222,520 |
| Axsome Therapeutics, Inc. · A Randomized, Double-Blind, Active-Controlled Study of Axs-05 for the Prevention of Relapse of Depressive Symptoms · 2024 | Their institution | $132,134 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2024 | Their institution | $111,408 |
| Allergan Inc. · Phase Iia US Pop W Sod 3125-201-002 · 2019 | Their institution | $96,666 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Iti-1284 As An Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have An Inadequate Response To Generalized Anxiety Disorder Treatment · 2025 | Their institution | $92,361 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 Mg As Adjunctive Therapy in Adult Participants With Major Depressive Disorder (Mdd) With Moderate-To-Severe Anhedonia An · 2025 | Their institution | $82,334 |
| ABBVIE INC. · A 52-Week, Phase 2, Open-Label Trial To Evaluate the Long-Term Safety and Tolerability of Cvl-231 (Emraclidine) in Adult Participants With Schizophrenia · 2025 | Their institution | $70,282 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 Mg and 5 Mg As Adjunctive Therapy in Adult Participants With Major Depressive Disorder (Mdd) With Moderate To Severe Anhedonia and Inadequate Response To Current Antidepressant Therapy. · 2024 | Their institution | $53,488 |
| ABBVIE INC. · Study To Assess Adverse Events and Change in Disease Activity When Oral Abbv-932 Is Added To Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder · 2025 | Their institution | $52,826 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder · 2023 | Their institution | $50,270 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine · 2024 | Their institution | $46,628 |
| PFIZER INC. · Phase 3 Multicenter Openlabel Study To Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2023 | This clinician | $43,080 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2022 | Their institution | $42,055 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40189 · 2022 | Their institution | $40,122 |
| Alkermes, Inc. · A Phase 3, Multicenter Study To Assess the Long Term Safety and Tolerability of Alks 3831 in Subjects With Schizophrenia · 2019 | Their institution | $36,815 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2024 | Their institution | $36,410 |
| ABBVIE INC. · A 52-Week, Phase 2, Open-Label Trial To Evaluate the Long-Term Safety and Tolerability Of00ffcvl-23100ff(Emraclidine) in Adult Participants With Schizophrenia · 2024 | Their institution | $36,042 |
| Alkermes, Inc. · Study To Evaluate the Long-Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 · 2019 | Their institution | $34,372 |
| Biohaven Pharmaceutical Holding Company Ltd. · Phase 3 Multicenter Randomized Double-Blind Group Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents ? 6 To <18 Years of Age · 2022 | Their institution | $32,529 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Connex-3 · 2024 | Their institution | $32,498 |
| PFIZER INC. · Phase 3 Multicenter Openlabel Study To Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2024 | Their institution | $32,480 |
| Biohaven Pharmaceutical Holding Company Ltd. · Phase 3 Multicenter Randomized Double-Blindgroup Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents = 6 To <18 Years of Age · 2022 | Their institution | $31,448 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6 Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2024 | Their institution | $28,901 |
| PFIZER INC. · Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study To Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2024 | Their institution | $28,286 |
| H. Lundbeck A S · A Trial of Eptinezumab in Participants With Migraine and Insufficient Response To Anti-Cgrp Medications · 2025 | Their institution | $28,037 |
| E.R. Squibb & Sons, L.L.C. · Open-Label Extension Study To Assess the Long-Term Safety and Tolerability of Karxt in Subjects With Psychosis Associated With Alzheimers Disease Dementia · 2025 | Their institution | $27,278 |
| PFIZER INC. · Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study To Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2025 | Their institution | $27,078 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Proof-of-Concept Study To Evaluate the Efficacy, Safety, and Tolerability of Jnj-89495120 As Monotherapy in Adult Participants With Major Depressive Disorder (Mdd) · 2025 | Their institution | $27,061 |
| ABBVIE INC. · Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2024 | Their institution | $27,049 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury (Tbi) · 2022 | Their institution | $26,919 |
| Sage Therapeutics, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due To Alzheimer'S Disease · 2024 | Their institution | $25,832 |
| ABBVIE INC. · A Study of Oral Atogepant Tablets To Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 To 17 Years · 2025 | Their institution | $25,441 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Connex-3 · 2025 | Their institution | $23,810 |
| Alkermes, Inc. · A Phase 3 Study To Evaluate Weight Gain of Alks 3831 Compared To Olanzapine in Adults With Schizophrenia · 2019 | Their institution | $23,705 |
| Janssen Research & Development, LLC · 2024 | Their institution | $23,480 |
| ABBVIE INC. · A 52-Week, Phase 2, Open-Label Trial To Evaluate the Long-Term Safety and Tolerability of?Cvl-231?(Emraclidine) in Adult Participants With Schizophrenia · 2024 | Their institution | $22,401 |
| PFIZER INC. · Phase 3 Multicenter Openlabel Study To Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2025 | Their institution | $22,290 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $21,581 |
| ABBVIE INC. · Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2025 | Their institution | $21,535 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine · 2023 | Their institution | $21,025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder · 2024 | Their institution | $20,930 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. · Phase 3 Multicenter Openlabel Study To Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2023 | Their institution | $20,863 |
| ABBVIE INC. · A Study To Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine · 2025 | Their institution | $20,803 |
| E.R. Squibb & Sons, L.L.C. · Open-Label Extension Study To Assess the Long-Term Safety and Tolerability of Karxt in Subjects With Psychosis Associated With Alzheimers Disease Dementia · 2024 | Their institution | $20,173 |
| Avanir Pharmaceuticals, Inc. · 2022 | Their institution | $19,688 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Connex 3 · 2023 | Their institution | $18,679 |
| ABBVIE INC. · Migraine Is A Common Neurological Disorder Typically Characterized By Attacks of Throbbing, Moderate To Severe Headache, Often Associated With Nausea, Vomiting, and Sensitivity To Light and Sound. Migraine Is Extremely Common and Disabling in Children. the Purpose of This Study Is To Evaluate Long Term Safety and Tolerability of Ubrogepant in the Acute Treatment of Migraine in Children and Adolescents. · 2022 | Their institution | $17,900 |
| Biohaven Pharmaceuticals, Inc. · Phase 3 Multicenter Randomized Double-Blindgroup Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents = 6 To <18 Years of Age · 2021 | Their institution | $17,897 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40189 · 2023 | Their institution | $17,829 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Arm Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Drobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia · 2022 | Their institution | $17,245 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate the Safety and Efficacy of Karxt for the Treatment of Psychosis Associated With Alzheimers Disease Dementia · 2025 | Their institution | $16,916 |
| Janssen Research & Development, LLC · A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (Mdd) (Ventura-Lt) · 2025 | Their institution | $15,750 |
| Sage Therapeutics, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due To Alzheimer'S Disease · 2023 | Their institution | $14,763 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2023 | Their institution | $14,575 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2023 | Their institution | $14,149 |
| Avanir Pharmaceuticals, Inc. · 2021 | Their institution | $13,000 |
| Biohaven Pharmaceuticals, Inc. · Phase 3 Multicenter Randomized Double-Blindgroup Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents ? 6 To <18 Years of Age · 2021 | Their institution | $12,540 |
| PFIZER INC. · Phase 3 Multicenter Openlabel Study To Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2023 | Their institution | $12,358 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deuterated [D6]-Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2023 | Their institution | $11,990 |
| PFIZER INC. · Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study To Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2023 | This clinician | $11,632 |
| ABBVIE INC. · Multicenter, Open-Label, Extension Study To Evaluate the Long-Term Safety and Tolerability of Abbv-932 in Subjects With Depressive Episodes Associated With Bipolar I Or II Disorder · 2025 | Their institution | $11,282 |
| ABBVIE INC. · A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Icalcaprant in Subjects With Major Depressive Disorder · 2025 | Their institution | $11,027 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40223 · 2025 | Their institution | $10,192 |
| Vanda Pharmaceuticals Inc. · Study To Evaluate the Efficacy and Safety of Vqw-765 for the on-Demand Treatment of Social Anxiety Disorder · 2025 | Their institution | $10,061 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40223 · 2022 | Their institution | $9,348 |
| Alkermes, Inc. · Study To Evaluate the Long-Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 · 2020 | Their institution | $9,162 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40223 · 2023 | Their institution | $9,016 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 Mg As Adjunctive Therapy in Adult Participants With Major Depressive Disorder (Mdd) With Moderate-To-Severe Anhedonia An · 2024 | Their institution | $8,466 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate the Safety and Efficacy of Karxt for the Treatment of Psychosis Associated With Alzheimers Disease Dementia · 2024 | Their institution | $8,398 |
| ABBVIE INC. · Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2023 | Their institution | $8,333 |
| ABBVIE INC. · A Study To Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder · 2025 | Their institution | $8,135 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40223 · 2024 | Their institution | $8,081 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder · 2022 | Their institution | $7,524 |
| ABBVIE INC. · M21-199 - Long-Term Extension Study To Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 To 17 Years of Age) With Episodic Migraine · 2025 | Their institution | $7,432 |
| ABBVIE INC. · Long-Term Extension Study To Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2022 | Their institution | $7,160 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2022 | Their institution | $6,685 |
| Avanir Pharmaceuticals, Inc. · 2019 | Their institution | $6,534 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of Avp-786 (Deuterated [D6] Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2024 | Their institution | $5,500 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2023 | Their institution | $5,348 |
| Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40189 · 2024 | Their institution | $4,931 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · Protocol 331-201-00080 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder · 2019 | Their institution | $4,392 |
| Boehringer Ingelheim RCV GmbH & Co KG · Connex 3 · 2023 | Their institution | $3,966 |
| ABBVIE INC. · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study To Evaluate the Efficacy, Safety, and Tolerability of Abbv-932 As An Adjunct To Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had An Inadequate Response To Antidepressant Therapies · 2025 | Their institution | $3,446 |
| ABBVIE INC. · A Multicenter, Open-Label, Extension Study To Evaluate the Long-Term Safety of Atogepant in Pediatric Subjects 6 To 17 Years of Age With Episodic Migraine · 2024 | Their institution | $3,420 |
| Alkermes, Inc. · A Phase 3 Study To Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, Or Bipolar I Disorder · 2021 | Their institution | $3,226 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia · 2023 | Their institution | $2,777 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deuterated [D6]-Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type · 2024 | Their institution | $2,626 |
| Alkermes, Inc. · Study To Evaluate the Long-Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 · 2023 | Their institution | $2,290 |
| ABBVIE INC. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Attack Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents (Ages 6-17) · 2024 | Their institution | $2,223 |
| Janssen Research & Development, LLC · A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 Mg and 5 Mg As Adjunctive Therapy in Adult Participants With Major Depressive Disorder (Mdd) With Moderate To Severe Anhedonia and Inadequate Response To Current Antidepressant Therapy. · 2025 | Their institution | $1,676 |
| Allergan, Inc. · Phase Iia US Pop W/ Sod (3125-201-002) · 2020 | Their institution | $1,499 |
| Eli Lilly and Company · A Phase 2 Multicenter, Double-Blind, Parallel-Arm Study To Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Adult Participants With Schizophrenia (Renew-Scz-1) · 2025 | This clinician | $1,456 |
| ABBVIE INC. · 3110-305-002 Ph3 Pivotal Peds Post Approval - Pmr (M21-265) · 2024 | Their institution | $1,440 |
| ABBVIE INC. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Attack Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $1,440 |
| ACADIA Pharmaceuticals Inc · Nuplazid · 2019 | This clinician | $1,255 |
| ABBVIE INC. · Multicenter, Open-Label Study To Evaluate the Long-Term Safety and Tolerability of Abbv-932 in Subjects With Depressive Episodes Associated With Bipolar I Or II Disorder · 2025 | Their institution | $1,222 |
| ABBVIE INC. · M21-201 Atogepant Ph3 Em Peds (3101-307-002) · 2024 | Their institution | $1,200 |
| ABBVIE INC. · A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age. · 2025 | Their institution | $1,200 |
| Boehringer Ingelheim RCV GmbH & Co KG · Connex-3 · 2024 | Their institution | $1,129 |
| ABBVIE INC. · A 52-Week, Phase 2, Open-Label Trial To Evaluate the Long-Term Safety and Tolerability of Cvl-231 (Emraclidine) in Adult Participants With Schizophrenia · 2024 | Their institution | $1,084 |
| Alkermes, Inc. · A Phase 3, Multicenter Study To Assess the Long Term Safety and Tolerability of Alks 3831 in Subjects With Schizophrenia · 2020 | Their institution | $1,050 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study To Evaluate the Safety and Efficacy of Karxt for the Treatment of Psychosis Associated With Alzheimers Disease · 2024 | Their institution | $842 |
| ABBVIE INC. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder · 2024 | Their institution | $840 |
| Biohaven Pharmaceutical Holding Company Ltd. · Phase 3 Multicenter Randomized Double-Blind Group Sequential Placebo-Controlled Study To Assess Efficacy and Safety of Rimegepant Or the Treatment of Migraine (With Or Without Aura) in Children and Adolescents 6 To <18 Years of Age · 2022 | Their institution | $807 |
| PFIZER INC. · Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study To Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 To 18 Years of Age · 2023 | Their institution | $807 |
| ABBVIE INC. · A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 To 17 Years of Age · 2025 | Their institution | $619 |
| ABBVIE INC. · Study To Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) · 2025 | Their institution | $601 |
| ABBVIE INC. · A Multicenter, Open-Label, Extension Study To Evaluate the Long-Term Safety and Tolerability of Atogepant in Pediatric Subjects 6 To 17 Years of Age With Migraine · 2025 | Their institution | $600 |
| ABBVIE INC. · Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. · 2022 | Their institution | $309 |
| AbbVie Inc. · 2020 | Their institution | $269 |
| ABBVIE INC. · Migraine Is A Common Neurological Disorder Typically Characterized By Attacks of Throbbing, Moderate To Severe Headache, Often Associated With Nausea, Vomiting, and Sensitivity To Light and Sound. Migraine Is Extremely Common and Disabling in Children. the Purpose of This Study Is To Evaluate Long Term Safety and Tolerability of Ubrogepant in the Acute Treatment of Migraine in Children and Adolescents. · 2023 | Their institution | $249 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate the Safety and Efficacy of Karxt for the Treatment of Agitation Associated With Alzheimers Disease · 2025 | Their institution | $85 |
Professional record
- NPI
- 1245367507
- Licence
- CA G9084California G9084: Current · expires 2027-10-31
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-27
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.